Skip to content
value.today
Tyra Biosciences, Inc. logo

Tyra Biosciences, Inc.

Tyra Biosciences, Inc. is listed today as Tyra Biosciences, Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Tyra Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2024$200 MPrivate placement after listing$50 to $250 million

Tyra Biosciences, Inc.: Private sale, Feb 2024

Investors in this round

21 investors had bought by the notice of Feb 13, 2024: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Tyra Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$200 M of $200 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alan Fuhrman · Executive Officer
  • Daniel Bensen · Executive Officer
  • Hiroomi Tada, M.D., Ph.D. · Executive Officer
  • Todd Harris, Ph.D. · Executive Officer, Director
  • Gilla Kaplan, Ph.D. · Director
  • Isan Chen, M.D. · Director
  • Jake Simson, Ph.D. · Director
  • Melissa McCracken, Ph.D. · Director
  • Nina Kjellson · Director
  • Rehan Verjee · Director
  • Robert More · Director
  • Sid Subramony, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan Fuhrman, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 13, 2024. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Tyra Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2024).

    SEC Form D · Feb 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2024

That is all the official record says: Tyra Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Tyra Biosciences, Inc. are on record.

Investors#

18 named in official filings. Open an investor to see everything it has backed.

Investors in Tyra Biosciences, Inc.
InvestorKindAmountRoundRoleSource
Alta Partners NextGen Fund II, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Alta Partners NextGen Fund II Management, LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Boxer Asset Management Inc.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Boxer Capital, LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Canaan 2020+ Co-Investment L.P. Series 7Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Canaan Partners 2020+ Co-Investment LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Canaan Partners XI LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Canaan XI L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Asset Management, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Global Healthcare Master Fund, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Private Healthcare Fund III LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Daniel BensenPersonnot statednot statedHeld Series A preferred stock (Form 3, 2021)SEC Form 3
Isan ChenPersonnot statednot statedHeld Series A and B preferred stock, director (Form 3, 2021)SEC Form 3
MVA Investors, LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
RA Capital Healthcare Fund LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Ra Capital Management, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
RA Capital Nexus Fund, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Todd HarrisPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Tyra Biosciences, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Tyra Biosciences, Inc.
NameRoleNamed in
Alan FuhrmanExecutive officerFeb 2024
Daniel BensenExecutive officerFeb 2024
Hiroomi Tada, M.D., Ph.D.Executive officerFeb 2024
Todd Harris, Ph.D.Executive officerFeb 2024
Gilla Kaplan, Ph.D.DirectorFeb 2024
Isan Chen, M.D.DirectorFeb 2024
Jake Simson, Ph.D.DirectorFeb 2024
Melissa McCracken, Ph.D.DirectorFeb 2024
Nina KjellsonDirectorFeb 2024
Rehan VerjeeDirectorFeb 2024
Robert MoreDirectorFeb 2024
Sid Subramony, Ph.D.DirectorFeb 2024
Todd Harris, Ph.D.DirectorFeb 2024

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.